ATE546540T1 - Verwendung massgeschneiderter rekombinasen zur behandlung von retrovirusinfektionen - Google Patents

Verwendung massgeschneiderter rekombinasen zur behandlung von retrovirusinfektionen

Info

Publication number
ATE546540T1
ATE546540T1 AT08706955T AT08706955T ATE546540T1 AT E546540 T1 ATE546540 T1 AT E546540T1 AT 08706955 T AT08706955 T AT 08706955T AT 08706955 T AT08706955 T AT 08706955T AT E546540 T1 ATE546540 T1 AT E546540T1
Authority
AT
Austria
Prior art keywords
tailored
genome
host cell
retrovirus
present
Prior art date
Application number
AT08706955T
Other languages
English (en)
Inventor
Joachim Hauber
Frank Buchholz
Ilona Hauber
A Stewart
Indrani Sarkar
Original Assignee
Heinrich Pette Inst Leibniz Inst Fuer Experimentelle Virologie Stiftung Buergerlichen Rechts
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heinrich Pette Inst Leibniz Inst Fuer Experimentelle Virologie Stiftung Buergerlichen Rechts, Max Planck Gesellschaft filed Critical Heinrich Pette Inst Leibniz Inst Fuer Experimentelle Virologie Stiftung Buergerlichen Rechts
Application granted granted Critical
Publication of ATE546540T1 publication Critical patent/ATE546540T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
AT08706955T 2007-01-08 2008-01-03 Verwendung massgeschneiderter rekombinasen zur behandlung von retrovirusinfektionen ATE546540T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100206A EP1942192A1 (de) 2007-01-08 2007-01-08 Verwendung einer massgeschneiderten Recombinase für die Behandlung einer retroviralen Erkrankung
PCT/EP2008/000021 WO2008083931A1 (en) 2007-01-08 2008-01-03 Use of a tailored recombinases for the treatment of retroviral infections

Publications (1)

Publication Number Publication Date
ATE546540T1 true ATE546540T1 (de) 2012-03-15

Family

ID=38179946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08706955T ATE546540T1 (de) 2007-01-08 2008-01-03 Verwendung massgeschneiderter rekombinasen zur behandlung von retrovirusinfektionen

Country Status (11)

Country Link
US (1) US8871516B2 (de)
EP (2) EP1942192A1 (de)
CN (1) CN101622356B (de)
AT (1) ATE546540T1 (de)
AU (1) AU2008204586B2 (de)
BR (1) BRPI0806492A2 (de)
CA (1) CA2674275C (de)
ES (1) ES2379206T3 (de)
RU (1) RU2501860C2 (de)
WO (1) WO2008083931A1 (de)
ZA (1) ZA200904561B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1942192A1 (de) 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Verwendung einer massgeschneiderten Recombinase für die Behandlung einer retroviralen Erkrankung
US20110015256A1 (en) * 2009-07-16 2011-01-20 Ihab Mamdouh Ishak Sadek Delivery of restriction endonucleases to treat hiv, cancer, and other medical conditions
CN103154256A (zh) 2010-05-27 2013-06-12 海因里希·佩特研究所莱比锡试验病毒学研究所－民法基金会 用于使多种逆转录病毒毒株中的不对称靶位点重组的修整重组酶
US12606824B2 (en) 2010-12-01 2026-04-21 Gowey Research Group, Pllc Micro-RNA profiling, compositions, and methods of treating diseases
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
CN104583398A (zh) * 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节基因表达的组合物和方法
ES2747833T3 (es) * 2013-04-04 2020-03-11 Dartmouth College Composiciones y procedimientos para la escisión in vivo del ADN proviral del vih-1
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection
EP2993229A1 (de) * 2014-09-02 2016-03-09 Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - Verträgliche und hochspezifische massgeschneiderte Rekombinase zur Rekombination asymmetrischer Zielorte in mehreren Retrovirenstämmen
RU2595373C1 (ru) * 2015-06-23 2016-08-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный аграрный университет имени Н.И. Вавилова" Набор для выявления днк провируса иммунодефицита крупного рогатого скота, содержащий пару специфичных праймеров и зонд, и способ диагностики вирусного иммунодефицита крупного рогатого скота методом полимеразной цепной реакции в режиме реального времени
EP3416663B1 (de) 2016-02-18 2021-04-14 The Penn State Research Foundation Erzeugung von gabaergenen neuronen im gehirn
WO2017213896A1 (en) * 2016-06-03 2017-12-14 Temple University - Of The Commonwealth System Of Higher Education Negative feedback regulation of hiv-1 by gene editing strategy
EP4039812B1 (de) * 2017-02-28 2025-06-11 The Penn State Research Foundation Regenerierende funktionelle neuronen zur behandlung von durch störungen der durchblutung verursachten neuronalen verletzungen
PL3638776T3 (pl) 2017-06-14 2026-02-23 Technische Universität Dresden Sposoby i środki do zmiany genetycznej genomów z wykorzystaniem projektowanych enzymów rekombinujących dna
EP3831939A1 (de) 2019-12-06 2021-06-09 Technische Universität Dresden Fusion von stellenspezifischen rekombinasen zur effizienten und spezifischen genom-editierung
MX2023003655A (es) 2020-09-29 2023-06-22 Neuexcell Therapeutics Inc Vector neurod1.
CA3232485A1 (en) 2021-11-15 2023-05-19 Technische Universitat Dresden Site-specific recombinases for efficient and specific genome editing
EP4455290A4 (de) * 2021-12-28 2025-11-26 Japan Chem Res Fusionsprotein eines anti-transferrin-rezeptorantikörpers und bioaktives protein für sichere gentherapie
CN116492476A (zh) * 2022-12-06 2023-07-28 上海交通大学 细菌T6SS核心组分VgrG作为药物递送载体的构建方法
EP4424822A1 (de) 2023-02-28 2024-09-04 PROVIREX Genome Editing Therapies GmbH Designer-rekombinase zur präzisen entnahme von htlv-1-provirus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU745960C (en) * 1997-11-18 2003-09-18 Pioneer Hi-Bred International, Inc. A novel method for the integration of foreign DNA into eukaryoticgenomes
AR021056A1 (es) * 1998-11-03 2002-06-12 Syngenta Participations Ag Adn que comprende un gen especifico de antera de arroz y planta transgenica transformada con el mismo
US6890726B1 (en) * 1999-04-06 2005-05-10 Oklahoma Medical Research Foundation Method for selecting recombinase variants with altered specificity
FR2814642B1 (fr) * 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
GB0029375D0 (en) 2000-12-01 2001-01-17 Total Fina Elf Substrate linked directed evolution (slide)
US20040229335A1 (en) * 2003-05-15 2004-11-18 Introgen Therapeutics, Inc. Methods and compositions for the production of adenoviral vectors
WO2005081632A2 (en) * 2004-02-26 2005-09-09 State Of Israel, Ministry Of Agriculture, Agricultural Research Organization Enzymes, cells and methods for site specific recombination at asymmetric sites
US20060014264A1 (en) * 2004-07-13 2006-01-19 Stowers Institute For Medical Research Cre/lox system with lox sites having an extended spacer region
EP1942192A1 (de) 2007-01-08 2008-07-09 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Verwendung einer massgeschneiderten Recombinase für die Behandlung einer retroviralen Erkrankung

Also Published As

Publication number Publication date
ZA200904561B (en) 2010-09-29
ES2379206T3 (es) 2012-04-23
BRPI0806492A2 (pt) 2014-04-22
RU2009130342A (ru) 2011-02-20
WO2008083931A1 (en) 2008-07-17
CN101622356B (zh) 2013-09-25
US8871516B2 (en) 2014-10-28
EP1942192A1 (de) 2008-07-09
CA2674275C (en) 2015-10-20
CN101622356A (zh) 2010-01-06
CA2674275A1 (en) 2008-07-17
US20100172881A1 (en) 2010-07-08
AU2008204586A1 (en) 2008-07-17
EP2094855B1 (de) 2012-02-22
RU2501860C2 (ru) 2013-12-20
AU2008204586B2 (en) 2011-08-11
EP2094855A1 (de) 2009-09-02

Similar Documents

Publication Publication Date Title
ZA200904561B (en) Use of a tailored recombinases for the treatment of retroviral infections
WO2011147590A3 (en) Tailored recombinase for recombining asymmetric target sites in a plurality of retrovirus strains
BRPI0811633A2 (pt) compostos de fórmulas (i) e (ii), método de tratamento de hospedeiro infectado por hiv-1, hiv-2, hbv ou hcv, método de prevenção de infecção por hiv-1, hiv-2, hbv ou hcv, método para reduzir atividade biológica de infecção por hiv-1, hiv-2, hbv ou hcv e composição farmacêutica
ATE494373T2 (de) Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle
EA201270108A1 (ru) Формирование полиспецифического t-клеточного ответа против вич у человека
EA201001273A1 (ru) Ингибиторы вируса гепатита с
NZ598000A (en) Composition for treating hbv infection
TW200730478A (en) N-(6-membered aromatic ring)-amido anti-viral compounds
WO2008133704A3 (en) Antimicrobial and antiviral compounds and methods for their use
MX387352B (es) Nuevos inhibidores de replicación viral.
WO2007084435A8 (en) Methods for treating hepatitis c
WO2010047830A3 (en) Agents for hcv treatment
WO2010060967A3 (en) Compositions and methods for treating retrovirus infections
EA201390810A1 (ru) Жидкие вирусные составы
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
HK1207871A1 (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2008124176A3 (en) Soluble and membrane-anchored forms of lassa virus subunit proteins
EA201001748A1 (ru) Соединения, используемые для лечения гепатита с
WO2009052090A8 (en) Silicate containing compositions and methods of treatment
EA201291179A1 (ru) Органические пероксидные соединения для инактивации микроорганизмов
WO2013037841A3 (fr) Genomes lentiviraux chimeriques non- integratifs comme vaccins contre hiv-1
WO2007098247A3 (en) Substituted taraxastanes useful for treating viral infections
EA201270798A1 (ru) Соединения для лечения гепатита с
WO2010099169A3 (en) A novel in vitro hiv-1 latency model for screening reactivation agents of hiv-1
BRPI0514476A (pt) inibidores da formação de cápsideo hiv-1: aril aminometil tiazol uréias substituìdas e análogos destas